TY - JOUR
T1 - Reply
AU - Oude Nijhuis, Renske A. B.
AU - Bredenoord, Albert J.
N1 - Funding Information: Conflicts of interest This author discloses the following: Albert J. Bredenoord received research funding from Nutricia, Norgine, and Bayer; and speaker and/or consulting fees from Laborie, EsoCap, Diversatek, Medtronic, Dr. Falk Pharma, Calypso Biotech, Thelial, Robarts, Reckett Benkiser, Regeneron, Celgene, Bayer, Norgine, AstraZeneca, Almirall, and Allergan. The remaining author discloses no conflicts. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85111110786&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.cgh.2020.10.030
DO - https://doi.org/10.1016/j.cgh.2020.10.030
M3 - Comment/Letter to the editor
C2 - 33248108
SN - 1542-3565
VL - 19
SP - 1988
EP - 1989
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 9
ER -